logo BDSP

Base documentaire


  1. Access to recombinant erythropoietin by medicare-entitled dialysis patients in the first year after FDA approval.

    Article - En anglais

    Objective.-Examine access to recombinant human erythropoietin (rHuEPO) by dialysis-dependent end-stage renal disease (ESRD) patients during the first year after FDA approval for use in clinical practice and Medicare coverage.

    Design.-Longitudinal and cross-sectional claims data analyses.

    Setting.-All US providers of outpatient dialysis treatment.

    Patients.-126 201 Medicare-entitled dialysis patients (~93% of all US dialysis patients).

    Outcome Measures.-Percentage of patients who received rHuEPO, odds of receiving rHuEPO according to patient characteristics, and cost of rHuEPO to Medicare.

    Mots-clés Pascal : Chronique, Appareil urinaire pathologie, Réanimation, Traitement, Homme, Chimiothérapie, Dialyse, Epuration extrarénale, Erythropoïétine, Etats Unis, Amérique du Nord, Amérique, Recombinant human erythropoietin, Accès soin

    Mots-clés Pascal anglais : Chronic, Urinary system disease, Resuscitation, Treatment, Human, Chemotherapy, Dialysis, Extrarenal dialysis, Erythropoietin, United States, North America, America

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 93-0560689

    Code Inist : 002B02O. Création : 199406.